80 related articles for article (PubMed ID: 11221954)
1. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs.
Takiguchi N; Saito N; Nunomura M; Kouda K; Oda K; Furuyama N; Nakajima N
Cancer Chemother Pharmacol; 2001; 47(1):11-4. PubMed ID: 11221954
[TBL] [Abstract][Full Text] [Related]
2. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors.
Stuhr LE; Iversen VV; Straume O; Maehle BO; Reed RK
Cancer Lett; 2004 Jul; 210(1):35-40. PubMed ID: 15172118
[TBL] [Abstract][Full Text] [Related]
3. Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells.
Peng ZR; Zhong WH; Liu J; Xiao PT
Undersea Hyperb Med; 2010; 37(3):141-50. PubMed ID: 20568543
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue].
Ono M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine.
Bezerra DP; de Castro FO; Alves AP; Pessoa C; de Moraes MO; Silveira ER; Lima MA; Elmiro FJ; de Alencar NM; Mesquita RO; Lima MW; Costa-Lotufo LV
J Appl Toxicol; 2008 Mar; 28(2):156-63. PubMed ID: 17541943
[TBL] [Abstract][Full Text] [Related]
6. Effects of hyperbaric oxygen on S-180 sarcoma in mice.
Lian QL; Hang RC; Yan HF; Chen T; Ni GT; Lu HQ; Liu YY; Liu XQ
Undersea Hyperb Med; 1995 Jun; 22(2):153-60. PubMed ID: 7633277
[TBL] [Abstract][Full Text] [Related]
7. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.
Xu Q; Brabham JG; Zhang S; Munster P; Fields K; Zhao RJ; Yu H
DNA Cell Biol; 2005 Jul; 24(7):470-5. PubMed ID: 16008516
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
9. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice.
Cao Z; Liao L; Chen X; Lan L; Hu H; Liu Z; Chen L; Huang S; Du J
Integr Cancer Ther; 2013 Mar; 12(2):174-81. PubMed ID: 22791308
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
12. Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits.
Haaga JR; Exner AA; Wang Y; Stowe NT; Tarcha PJ
Radiology; 2005 Dec; 237(3):911-8. PubMed ID: 16237145
[TBL] [Abstract][Full Text] [Related]
13. Comparative study between daily and 5-days-a-week administration of oral 5-fluorouracil chemotherapy in mice: determining the superior regimen.
Makino M; Shoji H; Takemoto D; Honboh T; Nakamura S; Kurayoshi K; Kaibara N
Cancer Chemother Pharmacol; 2001 Nov; 48(5):370-4. PubMed ID: 11761454
[TBL] [Abstract][Full Text] [Related]
14. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and antiangiogenic active dendrimer/5-fluorouracil conjugates.
Lee SM; Bala YS; Lee WK; Jo NJ; Chung I
J Biomed Mater Res A; 2013 Aug; 101(8):2306-12. PubMed ID: 23355500
[TBL] [Abstract][Full Text] [Related]
16. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
[TBL] [Abstract][Full Text] [Related]
18. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
19. Repetitive hyperbaric oxygen exposures enhance sensitivity to convulsion by upregulation of eNOS and nNOS.
Liu W; Li J; Sun X; Liu K; Zhang JH; Xu W; Tao H
Brain Res; 2008 Mar; 1201():128-34. PubMed ID: 18342297
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines.
Nishikawa T; Kohjimoto Y; Nishihata M; Ebisuno S; Hara I
Urology; 2009 Dec; 74(6):1370-6. PubMed ID: 19428092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
